Evolus’ (EOLS) Buy Rating Reiterated at Needham & Company LLC

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a report released on Thursday, Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 77.13% from the company’s current price.

Several other research firms have also issued reports on EOLS. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Tuesday, May 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Thursday, June 20th.

Evolus Stock Performance

Shares of EOLS opened at $12.42 on Thursday. The company has a market capitalization of $777.49 million, a PE ratio of -11.83 and a beta of 1.29. Evolus has a one year low of $7.44 and a one year high of $15.43. The company has a debt-to-equity ratio of 6.54, a current ratio of 3.21 and a quick ratio of 2.96. The company’s fifty day moving average price is $11.72 and its 200 day moving average price is $12.62.

Evolus (NASDAQ:EOLS) last announced its earnings results on Tuesday, May 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The company had revenue of $59.33 million for the quarter, compared to analysts’ expectations of $58.78 million. As a group, analysts expect that Evolus will post -0.61 earnings per share for the current year.

Insider Activity

In other Evolus news, insider David Moatazedi sold 16,051 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $12.72, for a total value of $204,168.72. Following the transaction, the insider now directly owns 673,563 shares in the company, valued at $8,567,721.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Evolus news, insider David Moatazedi sold 16,051 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $12.72, for a total value of $204,168.72. Following the completion of the transaction, the insider now directly owns 673,563 shares of the company’s stock, valued at $8,567,721.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sandra Beaver sold 2,423 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $30,820.56. Following the completion of the transaction, the chief financial officer now directly owns 151,778 shares of the company’s stock, valued at $1,930,616.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 184,895 shares of company stock worth $2,384,720. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Evolus

A number of institutional investors have recently modified their holdings of EOLS. Vanguard Group Inc. raised its stake in shares of Evolus by 37.9% during the third quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock worth $24,666,000 after buying an additional 741,451 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Evolus by 134.6% during the fourth quarter. SG Americas Securities LLC now owns 43,978 shares of the company’s stock worth $463,000 after buying an additional 25,234 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Evolus by 353.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,614 shares of the company’s stock worth $70,000 after buying an additional 5,155 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Evolus by 31.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,056 shares of the company’s stock worth $211,000 after buying an additional 4,803 shares during the last quarter. Finally, Semanteon Capital Management LP bought a new stake in shares of Evolus during the fourth quarter worth approximately $472,000. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.